Argos Therapeutics Shares Rise

Argos Therapeutics shares were 17% higher in early Wednesday morning trading after the the company said that the U.S. Food and Drug Administration agreed with its plan to continue its Adapt phase 3 trial evaluating Rocapuldencel-T in combination with sunitinib/standard-of-care treatment of newly diagnosed metastatic renal cell carcinoma (mRCC) in accordance with current protocol to 290 events.

Previously, the company said that it has continued to conduct the trial despite the recommendation by an independent data monitoring committee in February 2017 to terminate the trial for futility. The FDA also agreed to review a protocol amendment to increase the pre-specified number of events for the primary analysis of overall survival beyond 290 events, the company said.

By Caroline Williams